These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 18528297)

  • 1. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
    Acquavella N; Kluger H; Rhee J; Farber L; Tara H; Ariyan S; Narayan D; Kelly W; Sznol M
    J Immunother; 2008; 31(6):569-76. PubMed ID: 18528297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
    J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
    McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB
    Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
    Kammula US; White DE; Rosenberg SA
    Cancer; 1998 Aug; 83(4):797-805. PubMed ID: 9708948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
    Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S
    Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma.
    Eton O; Rosenblum MG; Legha SS; Zhang W; Jo East M; Bedikian A; Papadopoulos N; Buzaid A; Benjamin RS
    Cancer; 2002 Jul; 95(1):127-34. PubMed ID: 12115326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma.
    Legha SS; Gianan MA; Plager C; Eton OE; Papadopoulous NE
    Cancer; 1996 Jan; 77(1):89-96. PubMed ID: 8630945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of CNI-1493, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma.
    Atkins MB; Redman B; Mier J; Gollob J; Weber J; Sosman J; MacPherson BL; Plasse T
    Clin Cancer Res; 2001 Mar; 7(3):486-92. PubMed ID: 11297238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
    Amato RJ; Malya R; Rawat A
    Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
    Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma.
    Royal RE; Steinberg SM; Krouse RS; Heywood G; White DE; Hwu P; Marincola FM; Parkinson DR; Schwartzentruber DJ; Topalian SL; Yang JC; Rosenberg SA
    Cancer J Sci Am; 1996; 2(2):91-8. PubMed ID: 9166506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
    van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
    Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
    Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
    Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
    Shulman KL; Stadler WM; Vogelzang NJ
    Urology; 1996 Feb; 47(2):194-7. PubMed ID: 8607232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients.
    Sartore-Bianchi A; Soriani A; Mattioni R; Vaglio A; Buzio C; Porta C
    Oncol Rep; 2004 Oct; 12(4):855-9. PubMed ID: 15375512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
    NĂ©grier S; Perol D; Ravaud A; Bay JO; Oudard S; Chabaud S; Fargeot P; Delva R; Deplanque G; Gravis G; Escudier B;
    Clin Cancer Res; 2008 Sep; 14(18):5907-12. PubMed ID: 18794104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to reduce side effects of interleukin-2: evaluation of the antihypotensive agent NG-monomethyl-L-arginine.
    Kilbourn RG; Fonseca GA; Trissel LA; Griffith OW
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S21-30. PubMed ID: 10685654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
    McDermott DF; Atkins MB
    Semin Oncol; 2006 Oct; 33(5):583-7. PubMed ID: 17045087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.